EnteroBiotix, a Glasgow, Scotland-based biopharmaceutical company, raised $21m in Series A funding.
The round was led by Thairm Bio with participation from Kineticos Ventures, Scottish Enterprise and SIS Ventures.
The company intends to use the funds to further advance its microbiome drug pipeline and its product development and manufacturing capabilities and grow its headcount to around 50.
Led by Dr James McIlroy, CEO, EnteroBiotix is a biopharmaceutical company developing novel medicinal products that enhance the gut microbiome and target multiple disease indications. Established in 2017, EnteroBiotix also operates research laboratories and GMP pharmaceutical manufacturing suites in Glasgow and Aberdeen and owns a subsidiary operation called Number 2, which ensures the security and quality of supply of microbiota from human donors.